• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
WANG Kaizhen, YANG Wanwan, XU Shengyao, GUO Qinglong, ZHAO Li. Effects and mechanisms of AKR1C3 inducing doxorubicin resistance in breast cancer[J]. Journal of China Pharmaceutical University, 2021, 52(3): 352-360. DOI: 10.11665/j.issn.1000-5048.20210313
Citation: WANG Kaizhen, YANG Wanwan, XU Shengyao, GUO Qinglong, ZHAO Li. Effects and mechanisms of AKR1C3 inducing doxorubicin resistance in breast cancer[J]. Journal of China Pharmaceutical University, 2021, 52(3): 352-360. DOI: 10.11665/j.issn.1000-5048.20210313
shu

Effects and mechanisms of AKR1C3 inducing doxorubicin resistance in breast cancer

  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 210009, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81830105)
More Information
  • Received Date: March 04, 2021
  • Revised Date: May 12, 2021
    Graphical Abstract
    • Abstract
  • To explore the mechanisms by which AKR1C3 induces tumor resistance, human breast cancer cell strain MCF-7/DOX resistant to doxorubicin, MCF-7/ AKR1C3 cells for overexpression of AKR1C3 and MCF-7/DOX-KD cells for knockdown of AKR1C3 in MCF-7/DOX cells were established. Western blot analysis found that AKR1C3 was expressed at a higher level in MCF-7/DOX than MCF-7 wild type cells. Similarly, CCK-8 and DAPI confirmed that MCF-7/ AKR1C3 cells were more resistant to DOX than AKR1C3 wild types as the IC50 was increased 6 times in MCF-7/AKR1C3 cells more than in AKR1C3 wild type cells. Meanwhile, colony formation ability was also enhanced after AKR1C3 was over-expressed in MCF-7 cells.Cytoplasmic/nuclear separation analysis and IF further found that β-catenin nuclear translocation mediated by AKR1C3 was the main reason contributing to the occurrence of DOX-resistant breast cancer cells. β-catenin inhibitor, XAV939, could reverse the AKR1C3 induced doxorubicin resistance in MCF-7 cells.Results indicated that AKR1C3 could be a potential therapeutic target in breast cancer cells.
    • FullText(HTML)
    • References (15)
  • [1]
    . CA Cancer J Clin，2019，69（1）：7-34.
    [2]
    Xu ML，Wang C，Wang N，et al. MALAT1 upregulates SMYD3 by competition with miR-124 and promotes proliferation and migration of breast cancer cells［J］. J China Pharm Univ（中国药科大学学报），2019，50（3）：344-351.
    [3]
    Greenlee H，Dupont-Reyes MJ，Balneaves LG，et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment［J］. CA Cancer J Clin，2017，67（3）：194-232.
    [4]
    Howard GR，Johnson KE，Rodriguez Ayala A，et al. A multi-state model of chemoresistance to characterize phenotypic dynamics in breast cancer［J］. Sci Rep，2018，8（1）：12058.
    [5]
    Bandyopadhyay A，Wang L，Agyin J，et al. Doxorubicin in combination with a small TGFbeta inhibitor：a potential novel therapy for metastatic breast cancer in mouse models［J］. PLoS One，2010，5（4）：e10365.
    [6]
    Turton NJ，Judah DJ，Riley J，et al. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance［J］. Oncogene，2001，20（11）：1300-1306.
    [7]
    Penning TM，Burczynski ME，Jez JM，et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms （AKR1C1-AKR1C4） of the aldo-keto reductase superfamily：functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones［J］. Biochem J，2000，351（Pt 1）：67-77.
    [8]
    Penning TM. AKR1C3 （type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase）：roles in malignancy and endocrine disorders［J］. Mol Cell Endocrinol，2019，489：82-91.
    [9]
    Liu Y，He SY，Chen Y，et al. Overview of AKR1C3：inhibitor achievements and disease insights［J］. J Med Chem，2020，63（20）：11305-11329.
    [10]
    Boichuk S，Galembikova A，Sitenkov A，et al. Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance［J］. Oncol Lett，2017，14（4）：5039-5045.
    [11]
    Yamashita N，Kanno Y，Saito N，et al. Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells［J］. Biochem Biophys Res Commun，2019，516（3）：693-698.
    [12]
    Ruiz de Galarreta M，Bresnahan E，Molina-Sánchez P，et al. β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma［J］. Cancer Discov，2019，9（8）：1124-1141.
    [13]
    Tenbaum SP，Ordó?ez-Morán P，Puig I，et al. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer［J］. Nat Med，2012，18（6）：892-901.
    [14]
    Huang SM，Mishina YM，Liu SM，et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling［J］. Nature，2009，461（7264）：614-620.
    [15]
    Wu C，Yu S，Tan Q，et al. Role of AhR in regulating cancer stem cell-like characteristics in choriocarcinoma［J］. Cell Cycle，2018，17（18）：2309-2320.
    • Related Articles

  • Related Articles

    [1]YU Juping, LIU Wei, YE Meng, TANG Dongyang, GAO Xiangdong. Effect of homologous overexpression of nucleoside diphosphate kinase on the yield and molecular weight of hyaluronic acid[J]. Journal of China Pharmaceutical University, 2022, 53(2): 232-238. DOI: 10.11665/j.issn.1000-5048.20220214
    [2]JIANG Liya, LUO Ping, DENG Shaorong, YE Hao, YU Yan, HAN Wei. Antitumor effect of recombinant mouse interleukin-33 in mice[J]. Journal of China Pharmaceutical University, 2020, 51(5): 584-590. DOI: 10.11665/j.issn.1000-5048.20200510
    [3]LI Chengfei, CHEN Ling, WU Xuri. Regio-selective glycosylation of mogroside IIIE by glycosyltransferase[J]. Journal of China Pharmaceutical University, 2019, 50(2): 222-229. DOI: 10.11665/j.issn.1000-5048.20190214
    [4]JIN Yue, WU Xuri, CHEN Yijun. Applications of glycosyltransferases in the improvement of druggability of natural products[J]. Journal of China Pharmaceutical University, 2017, 48(5): 529-535. DOI: 10.11665/j.issn.1000-5048.20170504
    [5]XIA Yang, HU Lingling, CHEN Jiao, LU Wuguang, YAN Huaijiang, HUO Jiege, CAO Peng. Cloning and expression of recombinant BmkNaTx12, a new voltage-gated sodium channel from scorpion Buthus martensii Karsch[J]. Journal of China Pharmaceutical University, 2017, 48(2): 220-226. DOI: 10.11665/j.issn.1000-5048.20170214
    [6]WANG Yuanxi, CHEN Junsheng, SHAO Lei, LI Ji′an, LIN Huimin, CHEN Daijie. Heterologous expression and in vitro activity of vancomycin glycosyltransferase GtfE[J]. Journal of China Pharmaceutical University, 2013, 44(3): 272-276. DOI: 10.11665/j.issn.1000-5048.20130317
    [7]ZHAO Na, SUN Hong-bin. Poly(ADP-ribose) polymerase inhibitors and synthetic lethality[J]. Journal of China Pharmaceutical University, 2012, 43(2): 107-112.
    [8]LIN Yu-shuang, HONG Wen-rong. Construction of Streptomyces tenebrarius mutant with knockout of tobS1-C genes[J]. Journal of China Pharmaceutical University, 2012, 43(1): 92-96.
    [9]Construction of a high epidaunorubicin-producing strain by gene recombination[J]. Journal of China Pharmaceutical University, 2010, 41(3): 283-288.
    [10]PENG Chen, GE Hao, HE Shu-ying, GAO Xiang-dong. Molecular cloning，expression and identification of recombinant hyaluronan synthase from Pasteurella multocida[J]. Journal of China Pharmaceutical University, 2009, 40(6): 549-552.

  • Cited by

    Periodical cited type(1)

    1. 马小翔，马泽源，刘亚月，周龙建，和羿帆，张翼. 仿突变生物合成调控对土曲霉C23-3次生代谢产物的影响. 生物技术通报. 2024(08): 275-287 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (220) PDF downloads (621) Cited by(1)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365809

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return